Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 9/20 | 0.56 |
| ▸ | DBF4 | Q9UBU7 | 8/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 4/20 | 0.38 |
| ▸ | PLK4 | O00444 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | PRKACA | P17612 | 2/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | MARK3 | P27448 | 2/20 | 0.38 |
| ▸ | FLT4 | P35916 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.38 |
| ▸ | GSK3A | P49840 | 2/20 | 0.38 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.38 |
| ▸ | STK3 | Q13188 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12969827 | 0.86 | CDC7 (0.52) | CDC7DBF4MAPTIKBKBPLK4 | |
| SCHEMBL4901082 | 0.86 | CDC7 (0.64) | CDC7DBF4SLC6A3TMEM97MAPT | |
| SCHEMBL4901662 | 0.82 | IKBKB (0.52) | IKBKBCHUK | |
| SCHEMBL12969828 | 0.76 | CDC7 (0.48) | CDC7DBF4MAPTIKBKBPLK4 | |
| SCHEMBL12969722 | 0.73 | CDC7 (1.00) | CDC7DBF4MAPTIKBKBPLK4 | |
| SCHEMBL4893099 | 0.70 | CDC7 (0.69) | CDC7DBF4MAPTIKBKBPLK4 | |
| SCHEMBL4895369 | 0.70 | IKBKB (0.66) | IKBKBCHUK | |
| SCHEMBL12969830 | 0.70 | CDC7 (0.58) | CDC7DBF4MAPTIKBKBPLK4 | |
| SCHEMBL4903115 | 0.67 | IKBKB (0.60) | CDC7DBF4IKBKBPLK4AURKA | |
| SCHEMBL6276921 | 0.67 | IKBKB (0.68) | SLC6A3TMEM97IKBKBCHUKGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | CYWIN CHARLES L | 2008-01-10 | — | — | US | claimed |
| US-20050101601-A1 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | US | claimed |
| WO-2012131297-A1 | PYRIDO [3',2' :4,5] THIENO [3, 2-D] PYRIMIDIN- 4 - YLAMINE DERIVATIVES AND THEIR THERAPEUTICAL USE | BAELL JONATHAN BAYLDON (AU) | 2012-10-04 | — | — | WO | disclosed |
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | CYWIN CHARLES L | 2008-01-10 | — | — | US | disclosed |
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | CYWIN CHARLES L | 2008-01-10 | — | — | US | disclosed |
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | CYWIN CHARLES L | 2008-01-10 | — | — | US | disclosed |
| US-7291733-B2 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291733-B2 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291733-B2 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20050101601-A1 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101601-A1 | Substituted tricyclic heterocycles and their uses | LTC4S, NQO1, CBR3 | CDC7 1740/4885DBF4 2118/4885SLC6A3 4139/4885 |
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | LTC4S, NQO1, CBR3 | CDC7 1740/4885DBF4 2118/4885SLC6A3 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.